Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 28;12(4):e7868.
doi: 10.7759/cureus.7868.

Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature

Affiliations
Review

Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature

Faryal Tahir et al. Cureus. .

Abstract

Postural orthostatic tachycardia syndrome (POTS) is an autonomic disorder characterized by symptoms such as palpitations, dyspnea, chest discomfort, and lightheadedness affecting various systems. The pathophysiology of POTS is not completely understood due to a variety of symptoms showing that the disease is multifactorial. There is no approved uniform management strategy for POTS and hence, no drug has been approved by the United States (US) Food and Drug Administration (FDA) for it. Ivabradine is an FDA-approved drug for stable symptomatic heart failure (HF) and patients with an ejection fraction (EF) of ≤35%. Previous studies have depicted improvement in symptoms of POTS with the use of ivabradine. It is a selective inhibitor of funny sodium channels (If) in the sinoatrial (SA) node cells resulting in the prolongation of the slow diastolic depolarization (phase IV) and reduction in the heart rate (HR). Although beta-adrenoceptor blockers are commonly used to lower HR in patients with POTS, they are less ideal due to numerous adverse effects. This review aims to provide a comprehensive and up-to-date picture of all the studies and case reports that utilized ivabradine for the treatment of POTS along with a precise overview of epidemiology, pathophysiology, and types of POTS. To conclude, we recommend further research on the effectiveness of ivabradine in patients who experience symptoms of POTS. Other than stable chronic angina pectoris, its application in this setting has been proven to be effective and safe. Further evaluation by means of randomized control trials is required to encourage use of this HR-lowering agent in common disorders other than HF and stable angina, i.e. POTS.

Keywords: autoimmune pots; deconditioning pots; heart rate-lowering drug; hyperadrenergic pots; hypovolemic pots; ivabradine; neuropathic pots; postural orthostatic tachycardia syndrome; postural tachycardia syndrome; pots.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Diagnostic criteria for POTS
Adapted from [10]. POTS: postural orthostatic tachycardia syndrome
Figure 2
Figure 2. Structure of ivabradine
Adapted from [20].

Similar articles

Cited by

References

    1. On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. Da Costa JM. Am J Med Sci. 1951;11:559–567.
    1. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Schondorf R, Low PA. Neurology. 1993;43:132–137. - PubMed
    1. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Sheldon RS, Grubb BP, Olshansky B, et al. Heart Rhythm. 2015;12:0. - PMC - PubMed
    1. Postural orthostatic tachycardia syndrome: prevalence, pathophysiology, and management. Zadourian A, Doherty TA, Swiatkiewicz I, Taub PR. Drugs. 2018;78:983–994. - PubMed
    1. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. Fedorowski A. J Intern Med. 2019;285:352–366. - PubMed

LinkOut - more resources